In Part 1 of our Series on how the pharma landscape is being reshaped - from the inside out, we have Eyes On how cost discipline, manufacturing shifts, and portfolio resets are reshaping large pharma.

We've been keeping Eyes On the updates coming out along with the 2Q25 Results. Lots of news on strategic Plans, M&A, Clinical Data, and more. 

Lately, we've kept our Eyes On Sarepta Therapeutics and their discussions with the US FDA regarding their gene therapy Product Elevidys, their pipeline platform. All of this, plus the management shuffles at the FDA itself, has created quite a stir in the industry.

We've had Eyes on several firms that are actively executing on their strategic plans to ensure competitiveness in their markets. Take a look at how BioNTech, Novo Nordisk, and Merck are adapting to changing markets and technologies.

This week we've kept Eyes On the MFN and Tariff news, plus the Moderna x HHS Break-up and the Lilly x SiteOne Deal. The BioPharma Marketplace is in flux and we're watching to see how everyone is adapting and re-aligning their strategies.

We're catching up on the latest news and views surrounding the BioPharma Industry & Tariffs.

Just two weeks after our initial blogpost was published, 23andMe has made headlines again — this time for being acquired by Regeneron Pharmaceuticals in a deal valued at $256 million.

We've been keeping Eyes On Regulatory news, both in the US and Europe. We're sharing a few of the updates from the past few weeks on approval timing, staffing changes, clinical results, international company coalitions, and more.

JnJ, Legend expanding cell therapy capacity.

This month we've been watching how different companies are managing their pipelines, and keeping Eyes On other hot news topics.

We've highlighted a few firms: Lilly, AbbVie, Pfizer, Novo Nordisk, BMS, Roche, Novartis, Merck, AstraZeneca, GSK, Viatris, Teva, and Amgen.

We've had Eyes On some of the recent deals, results, and investor actions. Check out the happenings at Sanofi/Opella, Pfizer, Regeneron, and

Eye's on the Amgen data releases for gMG & Atopic Dermatitis, the BMS approval of Cobenfy for schizophrenia, and Pfizer's Oxbryta recall...

his week we've been looking at the competition heating up due to a combination of M&A, biosimilar entrants, and new clinical data ...

We've had our Eyes On recent data releases, commercial strategy updates, and some FDA updates. What caught your Eye last week?

The ASCO 2024 annual meeting took place from 31st May to 4th June. A number of firms presented data, and others used this as an opportunity

Check out this Top Drugs of 2023 list with links to interesting reports in PharmaTell Studio. Contact us for a trial.

We've been keeping Eyes On Deals & Raises in the BioPharma sector for the first quarter of 2024. Things seem to be heating-up ...

Lately we've been keeping Eyes On the corporate restructuring in the BioPharma sector. We've seen Big Pharma and BioTech refocusing ...

We've been trying to keep up with current events - here's some of what we've hay Eyes On this week.